Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
FCGR3A encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. Additionally we are shipping FCGR3A Proteins (35) and FCGR3A Kits (28) and many more products for this protein.
Showing 10 out of 326 products:
Human Monoclonal FCGR3A Primary Antibody for FACS - ABIN4896167
Hartl, Krauss-Etschmann, Koller, Hordijk, Kuijpers, Hoffmann, Hector, Eber, Marcos, Bittmann, Eickelberg, Griese, Roos: Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. in Journal of immunology (Baltimore, Md. : 1950) 2008
Human Monoclonal FCGR3A Primary Antibody for FACS - ABIN4896176
Markel, Seidman, Besser, Zabari, Ortenberg, Shapira, Treves, Loewenthal, Orenstein, Nagler, Schachter: Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. in PLoS ONE 2009
The study first identified that CNVs in the FCGR3A gene were associated with the risk of gout, and the CNV in the locus showed different distributions of frequency between gout patients and healthy subjects, particularly the frequency of the high FCGR3A copy number variant.
analysis of the assembly and surface expression of FcepsilonR1alpha in cells shows that CD16A associates equally well with human CD247 (show CD247 Antibodies) and FcepsilonR1gamma homodimers
low copy numbers of FCGR2A (show FCGR2A Antibodies) and FCGR3B (show CD16 Antibodies) to be common risk factors for systemic lupus nephritis (SLE) and ANCA-associated systemic vasculitis (AASV).
Memory-like differentiation resulted in enhanced IFN-gamma (show IFNG Antibodies) production triggered by leukemia targets or FcgammaRIIIa ligation within licensed NK cells, which exhibited the highest functionality of the NK cell subsets interrogated.
We developed a semi-mechanistic model including a target-mediated elimination component that accurately described rituximab PK in patients with CLL. This allowed us to show for the first time an influence of a baseline count of target antigen and the FCGR3A-158V/F polymorphism on rituximab target-mediated elimination.
When higher-affinity genotypes for FCGR2A (show FCGR2A Antibodies), FCGR3A (show CD16 Antibodies), and FCGR2C were considered together, they were associated with significantly increased tumor shrinkage and prolonged survival in response to HD-IL2 (show IL2 Antibodies)... this is the first study to show associations of FCGR genotypes with outcome following HD-IL2 (show IL2 Antibodies) treatment
FCGR3A (show CD16 Antibodies)-V158F polymorphism could be a specific marker for response to anti-TNFalpha (show TNF Antibodies) therapy in psoriasis patients.
The FCGR3A V allele correlated with the occurrence of late-onset neutropenia following rituximab treatment in patients with rheumatic diseases
farletuzumab has enhanced binding to FCGR3A-158V high-affinity receptor and has an enhanced clinical outcome in ovarian cancer patients with low baseline CA125 levels and at least 1 high-affinity allele of FCGR2A or FCGR3A
CXCR7 (show CXCR7 Antibodies) mediates CD14 (show NDUFA2 Antibodies)(+)CD16 (show CD16 Antibodies)(+) monocyte transmigration across the blood brain barrier, and is a potential therapeutic target for neuro AIDS.
This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
, Fc fragment of IgG, low affinity III, receptor for (CD16)
, Fc gamma receptor III-A
, Fc-gamma RIII-alpha
, Fc-gamma RIIIa
, Fc-gamma receptor III-2 (CD 16)
, Fc-gamma receptor IIIb (CD16)
, fc-gamma RIII
, igG Fc receptor III-2
, immunoglobulin G Fc receptor III
, low affinity immunoglobulin gamma Fc region receptor III-A
, neutrophil-specific antigen NA
, Fc fragment of IgG intermediate affinity IV receptor
, Fc fragment of IgG, low affinity IIIa, receptor for (CD16)
, transmembrane receptor FcgammaRIII-X